Drug Type Bispecific antibody, Fusion protein |
Synonyms anti-PD-L1 monoclonal antibody-VEGFR1 fusion protein, HB 0025, HB-0025 + [1] |
Target |
Mechanism PDL1 inhibitors(Programmed death-ligand 1 inhibitors), VEGF gene inhibitors(Vascular endothelial growth factor gene inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 2 | CN | 18 Jul 2023 | |
Kidney Neoplasms | Phase 2 | CN | 21 Feb 2023 | |
Advanced Endometrial Carcinoma | Phase 2 | CN | 02 Feb 2023 | |
Hepatocellular Carcinoma | IND Approval | CN | 10 Nov 2023 |
Phase 1 | Non-Small Cell Lung Cancer EGFR/ALK mutation | EGFR/ALK wild-type gene | 12 | epmbfljjsv(icplbyyjpn) = 33.3%, 4/12 wupinniyjm (tiariyvfuy ) View more | Positive | 24 May 2024 | ||
Phase 1/2 | 17 | oenuiwkwoi(cvuysnhriw) = umpmjmlumm vbwcvqiqwa (dpwiehbims, 1.7 - 40.5) View more | Positive | 24 May 2024 | |||
NCT04678908 (ASCO2023) Manual | Phase 1 | 30 | jynnfqvrbz(zxjzmbfesh) = toiwpqmxzh frjehuwsec (qgavyzdicw ) View more | Positive | 26 May 2023 |